Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
B Ponvilawan, AW Khan, J Subramanian, D Bansal - Cancers, 2024 - mdpi.com
Simple Summary Immune-related adverse events (irAEs) are one of the most common
complications after cancer treatment caused by immune checkpoint inhibitors (ICIs). We …
complications after cancer treatment caused by immune checkpoint inhibitors (ICIs). We …
Imaging of the Posttreatment Head and Neck: Expected Findings and Potential Complications
S Brahmbhatt, CJ Overfield, PA Rhyner… - Radiology: Imaging …, 2024 - pubs.rsna.org
Interpretation of posttreatment imaging findings in patients with head and neck cancer can
pose a substantial challenge. Malignancies in this region are often managed through …
pose a substantial challenge. Malignancies in this region are often managed through …
Recent updates on chimeric antigen receptor T-cell approaches in cancer immunotherapy
M Sahlolbei, A Ahmadieh-Yazdi… - Advances in Cancer …, 2024 - books.google.com
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary development in the field of
cancer immunotherapy, offering a targeted approach to combat various hematologic …
cancer immunotherapy, offering a targeted approach to combat various hematologic …
Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis
Background Persistent symptoms in hypothyroid patients despite normalized TSH levels
suggest the need for alternative treatments. This study aims to evaluate the effectiveness of …
suggest the need for alternative treatments. This study aims to evaluate the effectiveness of …
Emerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer
S Li, H Han, K Yang, X Li, L Ma, Z Yang… - International …, 2025 - Elsevier
The metabolic reprogramming of cancer cells is a hallmark of many malignancies. To meet
the energy acquisition needs of tumor cells for rapid proliferation, tumor cells reprogram their …
the energy acquisition needs of tumor cells for rapid proliferation, tumor cells reprogram their …
[HTML][HTML] Endocrine Adverse Events in Cancer Immunotherapy: From Mechanisms to Clinical Practice
O Aseyev, A Bishop, H Shortreed… - Advances in Cancer …, 2024 - intechopen.com
Immunotherapy-induced endocrinopathies remain an adverse risk factor for patients
undergoing PD-1/PD-L1 and CTLA-4 target immunotherapy treatment. Immunotherapy …
undergoing PD-1/PD-L1 and CTLA-4 target immunotherapy treatment. Immunotherapy …
[HTML][HTML] Immunotherapy-Related Hypothyroidism: Mechanisms and Management
SÇ Demir - 2024 - intechopen.com
Immunotherapy has recently emerged as an important tool in the treatment of various
malignancies. However, increased use of immune checkpoint inhibitors (ICIs) has brought …
malignancies. However, increased use of immune checkpoint inhibitors (ICIs) has brought …